Soligenix announces publication demonstrating civax™ booster induces rapid broad protection against covid-19 variants

Broader protection induced by combination of covid adenovirus vaccine plus civax ™  compared to 2-shot mrna vaccination series princeton, n.j. , march 25, 2025 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the preclinical efficacy of civax™, a thermostabilized subunit vaccine against sars-cov-2.
SNGX Ratings Summary
SNGX Quant Ranking